Cellectar Biosciences - Trendwende 2021/2022?
eröffnet am 06.03.21 15:35:22 von
neuester Beitrag 18.11.22 02:08:21 von
neuester Beitrag 18.11.22 02:08:21 von
Beiträge: 9
ID: 1.344.000
ID: 1.344.000
Aufrufe heute: 0
Gesamt: 1.201
Gesamt: 1.201
Aktive User: 0
ISIN: US15117F8077 · WKN: A3DQSD · Symbol: CLRB
3,0400
USD
-5,30 %
-0,1700 USD
Letzter Kurs 02:00:00 Nasdaq
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 0,9300 | +54,46 | |
| 0,5055 | +41,91 | |
| 6,8200 | +36,95 | |
| 2,4700 | +33,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0550 | -22,71 | |
| 2,4400 | -22,78 | |
| 6,0500 | -22,93 | |
| 0,9000 | -23,08 | |
| 1,2250 | -38,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
Secures license to the patents at issue in the lawsuit
FLORHAM PARK, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that Cellectar Biosciences, Inc., Wisconsin Alumni Research Foundation, and Drs. Jamey Weichert and Anatoly Pinchuk have resolved a lawsuit filed by Cellectar in October 2021 in the United States District Court for the Western District of Wisconsin concerning employee contracts and intellectual property rights in certain intellectual property pertaining to the diagnosis and treatment of cancer. The foregoing parties cannot further comment on that resolution, except to note that (i) all claims against Drs. Weichert and Pinchuk have been voluntarily dismissed, and (ii) Cellectar has secured an irrevocable, non-exclusive license to the patents at issue in the lawsuit.
The company has established exclusivity on a broad U.S. and international intellectual property rights portfolio around its proprietary cancer-targeting PLE technology platform, including iopofosine and its PDC programs.
In addition to the company’s exclusivity to iopofosine and its phospholipid ethers conjugated to small molecules, peptides, and oligos, the company now has non-exclusive rights to the use of the phospholipid ether platform when conjugating with a chelator to bind select metal radioisotopes.
FLORHAM PARK, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that Cellectar Biosciences, Inc., Wisconsin Alumni Research Foundation, and Drs. Jamey Weichert and Anatoly Pinchuk have resolved a lawsuit filed by Cellectar in October 2021 in the United States District Court for the Western District of Wisconsin concerning employee contracts and intellectual property rights in certain intellectual property pertaining to the diagnosis and treatment of cancer. The foregoing parties cannot further comment on that resolution, except to note that (i) all claims against Drs. Weichert and Pinchuk have been voluntarily dismissed, and (ii) Cellectar has secured an irrevocable, non-exclusive license to the patents at issue in the lawsuit.
The company has established exclusivity on a broad U.S. and international intellectual property rights portfolio around its proprietary cancer-targeting PLE technology platform, including iopofosine and its PDC programs.
In addition to the company’s exclusivity to iopofosine and its phospholipid ethers conjugated to small molecules, peptides, and oligos, the company now has non-exclusive rights to the use of the phospholipid ether platform when conjugating with a chelator to bind select metal radioisotopes.
Weiss jemand auf die schnelle welche News denn jetzt 2022 noch anstehen ..
DAAANKEEEEE
DAAANKEEEEE
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
CLRB
+9.64%
Cellectar Biosciences
Wed., December 8, 2021, 8:30 p.m.
In this article:
CLRB
+9.64%
FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced a poster presentation featuring data from the company’s ongoing Phase 2 CLOVER-1 study of iopofosine I-131 at the American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually December 11-14, 2021.
The poster will highlight data from eleven multiple myeloma patients who were at least triple class refractory (immunomodulatory agent, proteasome inhibitor and monoclonal antibody) that were treated with iopofosine I-131 in the company’s Phase 2 CLOVER-1 study, with data current as of the end of May 2021.
Details for the poster presentation are as follows:
Title:
CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 CLOVER-1 Trial
Session/Title:
653/Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I
Abstract:
1652
Authors:
Sikander Ailawadhi; Patrick Stiff; Emad Ibrahim; Damian J. Green; Brea Lipe; Elizabeth H. Cull; Natalie S. Callander; John Friend; Jarrod Longcor, and Kate Oliver
Date/Time:
Saturday, December 11, 2021 at 5:30 pm – 7:30 pm
A copy of the poster will be available after the presentation on the News and Events section of the company’s website.
About iopofosine (also known as CLR 131)
Iopofosine is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates iopofosine from many traditional on-market treatments. Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM.
CLRB
+9.64%
Cellectar Biosciences
Wed., December 8, 2021, 8:30 p.m.
In this article:
CLRB
+9.64%
FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced a poster presentation featuring data from the company’s ongoing Phase 2 CLOVER-1 study of iopofosine I-131 at the American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually December 11-14, 2021.
The poster will highlight data from eleven multiple myeloma patients who were at least triple class refractory (immunomodulatory agent, proteasome inhibitor and monoclonal antibody) that were treated with iopofosine I-131 in the company’s Phase 2 CLOVER-1 study, with data current as of the end of May 2021.
Details for the poster presentation are as follows:
Title:
CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 CLOVER-1 Trial
Session/Title:
653/Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I
Abstract:
1652
Authors:
Sikander Ailawadhi; Patrick Stiff; Emad Ibrahim; Damian J. Green; Brea Lipe; Elizabeth H. Cull; Natalie S. Callander; John Friend; Jarrod Longcor, and Kate Oliver
Date/Time:
Saturday, December 11, 2021 at 5:30 pm – 7:30 pm
A copy of the poster will be available after the presentation on the News and Events section of the company’s website.
About iopofosine (also known as CLR 131)
Iopofosine is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates iopofosine from many traditional on-market treatments. Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM.
Lesezeichen...
Trading Spotlight
Bin seit gestern dabei.
Auf geht's!
Auf geht's!
Antwort auf Beitrag Nr.: 67.404.155 von StellaVella am 10.03.21 19:42:49Zu bemängeln ist hier einzig die desaströse Kapitalbeschaffung der Vergangenheit, die u.a zu vielen warrants geführt hat, aber cash reicht locker bis weit über den readout hinaus.
Sehe hier $500-1b market cap in 1-2 Jahren
Sehe hier $500-1b market cap in 1-2 Jahren
Ich bin endlich dazu gekommen, hier mal ein bisschen DD zu betreiben. CLRB gefällt mir sehr gut! Der MOA ist einzigartig, mE und klingt universell anwendbar. Mit den Ergebnissen bisher hat die laufende Pivotalstudie für WM einen direkten Weg zum Fast-Track Approval.
Was mich besonders anspricht, ist die Technologie der Phospholipide, die rel. einfach modifiziert und mit einer anderen Payload versehen werden können. Mit anderen Worten: es handelt sich um eine Plattformtechnologie. Damit hat die Firma nicht nur einen Pfeil im Köcher.
Werde mir demnächst eine Position besorgen.
Was mich besonders anspricht, ist die Technologie der Phospholipide, die rel. einfach modifiziert und mit einer anderen Payload versehen werden können. Mit anderen Worten: es handelt sich um eine Plattformtechnologie. Damit hat die Firma nicht nur einen Pfeil im Köcher.
Werde mir demnächst eine Position besorgen.
Hallo zusammen,
da für Cellectar 2021 und 2022 wichtige Ereignisse anstehen, die einen Turnaround vervollständigen können, ist es Zeit für einen neuen Thread:
Dieses kleine Onkologie-Biotech hat wirklich viele Eisen im Feuer und mit seiner pivotalen Studie für Waldenstrom’s macroglobulinemia (WM) for BTKi failed or suboptimal response patients, die 2022 Daten liefern wird, einen effizienten Weg zum Approval. Attraktiv ist v.a. die geringe market cap bei Durchfinanzierung bis 2022 (fully diluted 80m shares, also etwa $130m market cap). In der Phase 2 hatten 5/6 eine response, und sogar eine mehrjährige CR war dabei (20% ORR wird für die pivotale Studie benötigt, also eine sehr geringe Hürde).
Die Phase 1/2 Ergebnisse für Multiple Myeloma waren ebenfalls sehr interessant, aber dafür verweise ich auf die Präsentation.
https://d1io3yog0oux5.cloudfront.net/_416c9c79cc01499fae4353…
Mit $57m in cash bei etwa $15m cash-burn p.a. wie gesagt für min. 2 Jahre komplett durchfinanziert, d.h. durch alle Readouts.
Sollte man auf jeden Fall beobachten, kann leicht ein x5-bagger werden bei weiterhin guten Ergebnissen.
@DWL33
@bcgk
@StellaVella
da für Cellectar 2021 und 2022 wichtige Ereignisse anstehen, die einen Turnaround vervollständigen können, ist es Zeit für einen neuen Thread:
Dieses kleine Onkologie-Biotech hat wirklich viele Eisen im Feuer und mit seiner pivotalen Studie für Waldenstrom’s macroglobulinemia (WM) for BTKi failed or suboptimal response patients, die 2022 Daten liefern wird, einen effizienten Weg zum Approval. Attraktiv ist v.a. die geringe market cap bei Durchfinanzierung bis 2022 (fully diluted 80m shares, also etwa $130m market cap). In der Phase 2 hatten 5/6 eine response, und sogar eine mehrjährige CR war dabei (20% ORR wird für die pivotale Studie benötigt, also eine sehr geringe Hürde).
Die Phase 1/2 Ergebnisse für Multiple Myeloma waren ebenfalls sehr interessant, aber dafür verweise ich auf die Präsentation.
https://d1io3yog0oux5.cloudfront.net/_416c9c79cc01499fae4353…
Mit $57m in cash bei etwa $15m cash-burn p.a. wie gesagt für min. 2 Jahre komplett durchfinanziert, d.h. durch alle Readouts.
Sollte man auf jeden Fall beobachten, kann leicht ein x5-bagger werden bei weiterhin guten Ergebnissen.
@DWL33
@bcgk
@StellaVella
DurchsuchenBeitrag schreiben
